Shares of Alvotech (ALVO) surged 9.15% in after-hours trading on Wednesday, following the release of the company's impressive financial results for the first half of 2025. The global biotech firm, specializing in biosimilar medicines, reported significant growth and a return to profitability.

Alvotech announced a net profit of $141.7 million, or $0.50 per share, for the first six months of 2025, marking a remarkable turnaround from the $153.5 million loss reported in the same period last year. The company's product revenue skyrocketed by over 200% year-on-year, reaching $204.7 million, driven by the expanded sales of its biosimilars AVT02 and AVT04 across key markets including the U.S., Canada, and Europe.

Despite a slight decrease in operating profit to $28.6 million from $43.4 million last year, Alvotech maintained a strong cash position of $151.5 million as of June 30, 2025. The company's robust performance was further bolstered by favorable changes in derivative liabilities and reduced finance costs. Investors seem particularly encouraged by Alvotech's continued investment in commercialization, regulatory progression, and pipeline development, signaling potential for sustained growth in the biosimilars market.